Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual MeetingGlobeNewsWire · 1 day ago Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial ContrastDefense World · Oct 9, 2026
Immatics (NASDAQ:IMTX) Reaches New 1-Year Low – Here’s WhyDefense World · Oct 9, 2026
Immatics (NASDAQ:IMTX) Sees Strong Trading Volume – Still a Buy?Defense World · Oct 2, 2026
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal MelanomaSeeking Alpha · Aug 25, 2026
Immatics Announces $150 Million Underwritten OfferingGlobeNewsWire · Aug 25, 2026Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 18, 2026 | -$0.48 | -$0.53 | Miss |
| May 12, 2026 | -$0.42 | -$0.50 | Miss |
| Mar 5, 2026 | -$0.48 | -$0.34 | Beat |
| Nov 17, 2025 | -$0.44 | -$0.49 | Miss |
| Aug 13, 2025 | -$0.38 | -$0.66 | Miss |
| May 13, 2025 | -$0.39 | -$0.35 | Beat |